Ansu Satpathy
@Satpathology
Followers
3K
Following
2K
Statuses
1K
immunotherapy, genomics, data, cancer @Stanford @Wing_VC @GladstoneInst @CartographyBio @Immunaitech @joinprox @parkerici
Joined July 2015
RT @StevenSalzberg1: 98% of NIH grants that should have gone out this month, didn't. Despite court orders 'unfreezing' the funds, they are…
0
702
0
More than 2/3 of new medicines are created by biotech and in-licensed by pharma, and nearly every innovative biotech comes from academia. That’s because it takes years and years of sustained and consistent focus and perseverance on a basic biological problem to lead to innovative drugs. This is not something that pharma can usually support. Youtube Jim Allison and checkpoint blockade. Yes, we can improve efficiency, but IMHO the NIH should come up with creative solutions to expand the pipeline and participate in the upside of medicines that it helps create, rather than severely cutting infrastructure for a key industry and opportunity for US growth.
13
37
181
RT @srikosuri: It’s been a tough few weeks. My 10yo daughter was diagnosed with a very rare, aggressive cancer called interdigitating dendr…
0
6K
0
0
0
2
RT @LabWaggoner: Low-avidity T cells drive endogenous tumor immunity in mice and humans @NatImmunol
0
20
0
RT @MLehrPHL: Musings on $VIR T cell engager data: ✅ CD3 is preferred immune effector for solid tumors ✅ Logic gating (masking, avidity, p…
0
2
0
PERFF-seq out in @NatureGenet ! Programmabale nucleic acid cytometry + scRNA-seq to study very rare cell types Such a joy to dream up crazy ideas with @CalebLareau @tsion_abay #BobStickels and occasionally they actually become a paper!
PERFF-seq is out today in @NatureGenet! Our recent thread summarizes why we are excited about the prospects of programmable nucleic acid cytometry for studying rare cell states.
0
1
28
1
0
5
RT @Montse_Rojo_PhD: In less than a month I’ll be heading back to Breckenridge to attend #KSPrecisionOnc25! See you there ❄️ @Cancer_Cell…
0
2
0
beautiful study and method for high-content cancer drug screening from @genophoria @iamjohnnyyu !
Our latest from the indefatigable @iamjohnnyyu in collaboration with @JswLab and @kevansf. Meet GENEVA, which enables simultaneous phenotyping and profiling of cancer cell drug responses at scale; both in vitro and in vivo across a variety of models:
0
3
8
RT @mfgrp: Today we report that an engineered skin bacterium, swabbed gently on the head of a mouse, can unleash a potent antibody response…
0
251
0
RT @maya_arce_: Excited to share the latest from the @MarsonLab! An investigation of context-specific gene regulation in T cells, which led…
0
29
0
RT @John_E_Connolly: Fantastic study by @lawfong @parkerici Evolution of myeloid-mediated immunotherapy resistance in prostate cancer |…
0
8
0
RT @PeterKolchinsky: Today brought new progress in the battle against disease. I see it because I'm in the biotech weeds. Every day brings…
0
38
0
RT @CarolynBertozzi: Cool preprint by @MichaelLDustin and coworkers on how various T cell engager formats, w/varying geometries/rigiditie…
0
8
0
RT @613weilin: Excited to share our latest preprint on scE2G – a new model to link enhancers to target genes using single-cell data – with…
0
8
0
Our collaboration with @samuels_yardena and @NCIEytanRuppin is out in @CD_AACR ! Why do genetically similar tumors show dramatic differences in immune rejection? We used temporal single-cell genomics of rejection + CRISPR screens to identify a potential cause related to macrophage response.
Temporal Genomic Analysis of Homogeneous Tumor Models Reveals Key Regulators of Immune Evasion in #Melanoma - by Sapir Cohen Shvefel, @joyp_ai, @NCIEytanRuppin, @Satpathology, @samuels_yardena, and colleagues @stanfordimmuno @WeizmannScience
0
4
32
Congratulations to my mentor, colleague, and friend @HowardYChang ! Howard is a once-in-a-generation scientific mind and leader and will transform drug discovery at Amgen and throughout the industry.
I am excited to join storied biotech pioneer @Amgen as Chief Scientific Officer and Head of Research. I look forward to partnering with my new colleagues to deepen understanding of biology and develop solutions to the most pressing medical challenges
0
5
77
LY6G6D is the next DLL3
We had a productive day in Houston at the 39th Annual Meeting of #SITC24 last week, engaging with industry experts and presenting #preclinical data on LY6G6D. We appreciate everyone who visited our poster to learn more about our efforts toward advancing CB21 for MSS CRC patients.
2
4
18